Microdosing

Microdosing refers to the practice of taking very small quantities of a psychedelic substance at regular intervals over days or weeks. In the context of LSD and psilocybin, the defining characteristic is sub-hallucinogenic: doses small enough that the characteristic features of a full experience -- vivid visual distortion, dissolution of self-boundaries, loss of functionality -- do not occur.

The term 'sub-perceptual' circulates widely in popular writing, but researchers increasingly find it imprecise. A more accurate description is that microdoses produce subtle, identifiable shifts in mood, attention, and temporal processing that a person can notice upon reflection, without the dramatic phenomenology of a larger experience. The brain is affected; the ordinary sense of self and reality generally remains intact.

The line between a microdose and a low dose is not fixed. Effects begin to emerge at a certain threshold and intensify continuously. This gradual continuum is one reason individual responses vary so much.

Albert Hofmann, who first synthesized LSD in 1938 and discovered its effects accidentally in 1943, expressed late-in-life interest in very low doses as a possible tool for mood and wellbeing. His comments have been widely cited in microdosing literature.

The contemporary practice traces more directly to James Fadiman, a psychologist who had been studying psychedelics and creativity since the 1960s. Around 2011, Fadiman began collecting informal self-reports from people using LSD or psilocybin on low-dose schedules and described his observations publicly. By the mid-2010s, the concept had found a receptive audience in Silicon Valley, where it spread as a reported tool for focus and creative output. Media coverage amplified the narrative considerably.

The cultural story that emerged -- that microdosing reliably enhances cognition, mood, and creativity -- outpaced what the evidence could support. Early data came almost entirely from open-label self-report. People who chose to microdose, expected it to work, and tracked their own results were not well-positioned to separate pharmacological effects from expectation.

Paul Stamets, the mycologist and psilocybin advocate, contributed a different thread to the microdosing conversation: a proposed combination of psilocybin mushrooms with lion's mane (a functional mushroom with potential neuroprotective properties) and niacin. The combination attracted considerable interest, though its specific synergistic claims have not been rigorously tested.

Across observational studies and survey data, the most consistently reported effects on dosing days are improvements in mood, a sense of increased focus or energy, and greater emotional fluency. Some people describe a mild brightening of sensory experience -- colors that feel more vivid, sounds that feel more present -- without anything approaching hallucination. Others notice almost nothing.

Cognitive effects are more mixed in the data. Some participants show reduced attentional lapses and subtle improvements in tasks that reward sustained focus. Time perception often shifts: longer intervals may feel shorter, or vice versa. Claims about creativity are among the most widely circulated, but also among the most contested -- some studies find modest improvements in divergent thinking, others find none, and unblinded designs tend to show much larger effects than blinded ones.

Emotional texture varies meaningfully by individual. Some people report feeling more emotionally available -- more likely to notice what they are feeling and name it. Others report anxiety, emotional volatility, or a sense of low-grade stimulation that is unwelcome.

Energy and motivation are frequently mentioned, but again appear to be acute rather than cumulative. The metaphor of a subtle upshift -- not a jolt, more a gentle brightening -- recurs in qualitative accounts. Whether that upshift is pharmacological, expectancy-driven, or some combination remains an open question.

Controlled research on microdosing is still relatively young. Early studies were largely open-label and observational -- informative for generating hypotheses, but structurally unable to separate drug effects from expectation. The field has since moved toward double-blind, placebo-controlled designs, with more cautious results.

A landmark study found that a substantial portion of reported improvements disappeared or shrank dramatically when participants could not tell whether they had taken a microdose or a placebo. Expectancy effects -- what people believed they had taken -- accounted for a meaningful share of positive outcomes. Other research has contested this conclusion, documenting neurobiological changes (altered network connectivity, increased neural complexity) that distinguish microdoses from placebo at the group level.

The honest current summary is this: there is evidence that microdosing produces real neurobiological effects, including modest changes in default mode network activity, serotonin receptor engagement, and neural complexity. Effects appear highly sensitive to individual baseline states, set and setting, and the degree to which expectation shapes interpretation.

Full-dose therapeutic research (such as psilocybin-assisted therapy for depression) is sometimes cited as validation for microdosing. The two contexts differ enough that this extrapolation is unreliable. High-dose therapeutic work depends on specific mechanisms -- profound shifts in self-perception, meaning-making, integration -- that have no parallel in low-dose repeated administration.

The every-third-day approach

Associated with James Fadiman's early observations, this cadence involves taking a dose one day, resting the next two days, then repeating. The two rest days are understood to allow effects to settle and reduce the risk of tolerance accumulation. Proponents of this approach often keep a journal tracking mood, energy, focus, and sleep across both dosing and non-dosing days -- the off-days being considered as informative as the on-days.

The adaptogenic stack

Paul Stamets has described a combination of psilocybin mushrooms alongside lion's mane mushroom and niacin (vitamin B3), taken on a rotating schedule. The rationale involves potential synergies between the psychedelic component, the proposed neuroprotective properties of lion's mane, and the peripheral vasodilation effect of niacin, which may help distribute compounds more evenly. The combination is widely discussed but has not been tested in controlled trials as a combined protocol.

Intuitive and flow-based approaches

Some people prefer less structured schedules, dosing when a particular day feels appropriate rather than following a fixed cadence. This approach prioritizes responsiveness to one's own nervous system and circumstances over protocol consistency. It is harder to study for obvious reasons, and carries a higher risk of gradual dose drift or increased frequency over time.

Tracking and reflection

Most structured approaches include consistent journaling across multiple weeks, tracking not just dosing days but non-dosing days as well. Sleep quality, social ease, creative output, and emotional tone tend to be the most useful dimensions to observe. The weeks-long arc -- not individual days -- is where patterns become legible.

Microdosing is not risk-free, and the popular framing of it as a mild, benign practice understates some genuine concerns. Anxiety and emotional volatility are among the most commonly reported adverse effects, appearing in roughly one in ten people in observational data. For those with pre-existing anxiety, the stimulant-adjacent quality of a microdose can intensify rather than relieve symptoms.

Chronic agonism of serotonin 5-HT2B receptors -- the receptor subtype associated with cardiac valvular changes in conditions like carcinoid syndrome -- is a concern that has been raised in the microdosing literature. The risk is thought to be dose-dependent and most relevant over very long durations of use. It remains understudied at microdose levels, but it is a sufficient reason to treat long-term daily or near-daily use with caution.

Sleep is frequently disrupted, particularly when microdosing later in the day. LSD has a long half-life; effects can persist for six to ten hours. Psilocybin clears faster, but some stimulant quality can still interfere with sleep onset. Tolerance to subjective effects can develop with frequent dosing, which may prompt gradual escalation -- moving from microdose into low-dose territory without noticing the shift.

The value of a microdosing period -- for those who find it useful -- tends to emerge over weeks rather than individual sessions. The more interesting question is what patterns appear across time: whether mood baseline shifts, whether certain kinds of work feel more accessible, whether sleep or social ease changes in either direction.

Journaling is often recommended not as a productivity practice but as a way of noticing. The practice of writing a brief daily note -- mood on waking, energy through the afternoon, sleep quality -- creates a record that is far more informative than memory alone. Off-days are as important to track as dosing days.

Integration in the microdosing context is less dramatic than integration after a full psychedelic experience, but the underlying idea is similar: the practice gains meaning through attention and reflection, not through the dosing days alone. Some people find that a microdosing period surfaces emotional material -- old patterns, habitual tensions -- that benefits from being worked with intentionally rather than just noticed.

Can microdosing psilocybin help with ADHD?

Research is promising but preliminary. A 2024 observational study (PMC) found self-reported improvements in attention and impulsivity among adults who microdosed psilocybin, but these were open-label findings without placebo controls. The neurological overlap between psychedelic-related serotonin modulation and attention regulation is plausible, but clinical evidence does not yet support microdosing as a treatment for ADHD. Anyone managing ADHD with prescribed medication should be aware of potential interactions.

Does microdosing help with depression?

This is different from full-dose psilocybin-assisted therapy for depression, which has a growing clinical evidence base. For microdosing specifically, some observational and survey studies report mood improvements, but blinded placebo-controlled trials have found that a meaningful portion of reported benefits disappear when participants cannot tell whether they received an active dose or a placebo. Current evidence suggests microdosing may produce real neurobiological effects, but whether these translate reliably into antidepressant outcomes for most people remains uncertain.

Can microdosing help with OCD?

Research on microdosing specifically for OCD is very early and largely anecdotal. Full-dose psychedelic experiences have more documented exploration in OCD contexts, where the disruption of rigid, repetitive thought patterns may be relevant. Some people with OCD report benefit from microdosing in self-report data, but there are no controlled trials. For OCD managed with SSRIs, there may also be pharmacological interactions worth discussing with a prescriber.

What about microdosing for chronic pain?

An emerging area of interest. Some research on psychedelics and neuroplasticity suggests they may help reshape maladaptive pain processing pathways, and anecdotal reports of reduced pain sensitivity and improved pain tolerance exist in the microdosing literature. However, dedicated clinical research on microdosing for chronic pain is very limited. This is not an area where current evidence supports firm conclusions.

Is daily microdosing safe?

Most structured protocols -- including James Fadiman's every-third-day approach and Paul Stamets' stack -- explicitly include off days, partly to limit tolerance accumulation and partly out of caution about long-term daily agonism of serotonin receptors. Chronic daily stimulation of 5-HT2B receptors has been associated with cardiac valvular changes in other contexts (carcinoid syndrome), and while the risk at microdose levels is not established, it is a reason most researchers recommend against daily dosing. Daily use also increases the risk of gradual dose escalation as tolerance develops.